AAV Gene Therapy — Optimizing Scale-Up to 2,000 L in Upstream Processing
About this webinar
Join this webinar to examine scale-up optimizations of AAV gene therapy in upstream processing. The featured speaker will explore both process characterization and experimental approaches to better understand key process steps, such as mixing dynamics and transfection cocktail maturation kinetics. Optimization knowledge is introduced into the process to improve yield and recovery at the 2,000 L scale.
Viralgen specializes in the large-scale cGMP production of AAV gene therapy vectors using their proprietary suspension, triple transfection platform. This platform includes the Pro10™ animal origin free and suspension-adapted cell line, a scalable upstream and robust purification process, coupled with full support for fill and finish, QC testing and regulatory guidance from preclinical to commercial requirements.
Who should attend
Therapeutic developers using AAV in the manufacture of cell and gene therapies
Featured Speakers
Silvia Gomez, PhD
Silvia Gomez currently works at Viralgen Commercial Therapeutic Vector Core as MSAT Head, responsible for technology transfer, scale up to 2000L and handling deviation from GMP batches. Silvia has eight years of prior experience in molecular biology and virology for basic and translational research and six years of CDMO experience at 3P Biopharmaceuticals (being responsible for technology transfer, scale-up and fill and finish in the last three years). Dr. Gomez has a degree in biochemistry and PhD in biomedical research.
Partner for this event
Viralgen
Viralgen, an independently operated Contract Development and Manufacturing Organization (CDMO), was founded in 2017 as a joint venture between AskBio and Columbus Venture Partners (a venture capital firm based in Spain). As one of the world’s leading manufacturers of cGMP-certified AAV, Viralgen uses the Pro10™ based suspension manufacturing platform, a technology licensed from AskBio and developed by co-founder R. Jude Samulski, PhD, at University of North Carolina. Pro10™ increases scalability, performance and precision of AAV therapies. Located in Spain, in the Gipuzkoa Science and Technology Park, Viralgen produces AAV gene therapy treatments for pharmaceutical and biotech companies with the aim of accelerating the delivery of new treatments that can improve patients’ lives.
Read more...
Viralgen has more than 420 employees, with three quarters of these holding advanced degrees. This talented workforce supports a range of core capabilities in quality assurance, quality control, analytical development and process development, all of which are critical to shortening the time to market and supporting customers with the regulatory process.
Read Less...
